FGP
BBNX

Freestone Grove Partners’s Beta Bionics BBNX Stock Holding History

Freestone Grove Partners’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-138,138
Closed -$4.21M – 1213
2025
Q4 		$4.21M Buy
+138,138
New +$3.69M 0.03% 361

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Freestone Grove Partners's BBNX Position: Q1 2026 in Review

Freestone Grove Partners sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 138,138 shares — an estimated $4.21M sold.

Freestone Grove Partners first reported a position in BBNX in Q4 2025 and held it in 1 quarter. The position peaked at $4.21M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Freestone Grove Partners reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 138,138 Beta Bionics shares in Q1 2026, an estimated $4.21M.
  • Freestone Grove Partners first reported a position in Beta Bionics in Q4 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Beta Bionics position peaked at $4.21M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.